EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Optimising Haematopoietic Stem Cell Transplantation: Enhancing Myeloablation Sensitivity and Alleviating Anaemia Using Roxadustat ( FG ‐4592)

Guanheng Yang, Jiahui Wu, Xinbing Guo, Wenchen Shen, Xiao Sang, Xiuli Gong, Shu-Zhen Huang, Jingzhi Zhang, Fanyi Zeng

Cell Proliferation · 2026-11 · 59 (11)

DOI: 10.1111/cpr.70230 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Proliferation, online erschienen am 10.07.2026. Verfasst von Guanheng Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Medical Genetics, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Isoquinolines, Glycine, Anemia, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Innovative Research Team of High-Level Local University in Shanghai.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Haematopoietic stem cell transplantation (HSCT) is an effective therapy for a broad range of hematologic, autoimmune and genetic diseases. Successful HSCT requires adequate myeloablation to create space in the bone marrow microenvironment for donor haematopoietic stem and progenitor cells. Standard conditioning with busulfan and cyclophosphamide (BuCy), although widely used, may not completely clear recipient cells and can cause significant toxicity. Roxadustat (FG‐4592), a hypoxia‐inducible factor prolyl hydroxylase inhibitor used to treat renal anaemia, modulates HIF‐1α stability and influences erythropoiesis, iron metabolism and cellular stress responses. Here, we investigated whether co‐administration of FG‐4592 during BuCy conditioning improves myeloablation efficiency and enhances donor‐cell engraftment. Our results show that FG‐4592 increases the sensitivity of bone marrow mononuclear cell (BM‐MNC) populations to BuCy conditioning, promoting deeper depletion of both haematopoietic and non‐haematopoietic recipient cells. This improved clearance supports enhanced donor‐cell residency following transplantation. Furthermore, in β 654 thalassaemia mice, FG‐4592 alleviated anaemia and reduced splenic iron deposition after HSCT. These findings suggest that FG‐4592 can serve as an effective adjuvant to standard myeloablation regimens, supporting improved engraftment and hematologic recovery. To our knowledge, this is the first study demonstrating that a HIF‐PH inhibitor can enhance conditioning efficiency during HSCT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IsoquinolinesGlycineAnemiaHematopoietic Stem Cell TransplantationTransplantation ConditioningAnimalsCyclophosphamideMiceBusulfanbeta-ThalassemiaMice, Inbred C57BLHematopoietic Stem CellsBone Marrow Cells

Stichwörter der Autor:innen

Roxadustat (FG‐4592)bone marrow microenvironmenthaematopoietic stem cellmyeloablationthalassaemiatransplantation

Substanzen

roxadustatIsoquinolinesGlycineCyclophosphamideBusulfan

Autor:innen und Institutionen

  • Shanghai Institute of Medical Genetics, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Histology, Embryology, Genetics and Developmental Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • NHC Key Laboratory of Medical Embryogenesis and Developmental Molecular Biology, Shanghai Key Laboratory of Embryo and Reproduction Engineering, Shanghai, China.
  • School of Pharmacy, Macau University of Science and Technology, Macau, China.

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Innovative Research Team of High-Level Local University in Shanghai
  • Macau Science and Technology Development Fund (FDCT)
  • Fundo para o Desenvolvimento das Ciências e da Tecnologia

Zitieren

APA

Yang, G., Wu, J., Guo, X., Shen, W., Sang, X., Gong, X., Huang, S. Z., Zhang, J., & Zeng, F. (2026). Optimising Haematopoietic Stem Cell Transplantation: Enhancing Myeloablation Sensitivity and Alleviating Anaemia Using Roxadustat ( FG ‐4592). Cell Proliferation, 59(11). https://doi.org/10.1111/cpr.70230

Vancouver

Yang G, Wu J, Guo X, Shen W, Sang X, Gong X, et al. Optimising Haematopoietic Stem Cell Transplantation: Enhancing Myeloablation Sensitivity and Alleviating Anaemia Using Roxadustat ( FG ‐4592). Cell Proliferation. 2026;59(11). doi:10.1111/cpr.70230

BibTeX
@article{Yang2026,
  author = {Yang, Guanheng and Wu, Jiahui and Guo, Xinbing and Shen, Wenchen and Sang, Xiao and Gong, Xiuli and Huang, Shu-Zhen and Zhang, Jingzhi and Zeng, Fanyi},
  title = {Optimising Haematopoietic Stem Cell Transplantation: Enhancing Myeloablation Sensitivity and Alleviating Anaemia Using Roxadustat ( FG ‐4592)},
  journal = {Cell Proliferation},
  year = {2026},
  volume = {59},
  number = {11},
  doi = {10.1111/cpr.70230}
}
Kostenlos starten →